Loading company…
Micot is a Xi'an biotech developing bi- and multi-specific peptide drugs for metabolic and cardiovascular diseases.
Established in 2007 and based in Xi'an, China, Micot (Shaanxi Micot Pharmaceutical Technology Co., Ltd.) develops bi- and multi-specific peptide drugs for metabolic, cardiovascular and cerebrovascular diseases. Its core product MT1013 targets CaSR and the OGP receptor. One pipeline completed Phase III trials in 2024. The company became a joint stock company in January 2025, and in June 2026 raised about HKD 1.06 billion in an IPO on HKEX under ticker 2335, at CNY 18.2 per share.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in